Orphazyme burned through millions of dollars in futile fight for success

Biotech is an expensive business, something Orphazyme can attest to. Over the years, it spent hundreds of millions of dollars developing its main asset, without ever crossing the finish line.
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
by christian bundgaard, translated by catherine brett

Despite its best efforts, biotech firm Orphazyme never managed to make an approved drug out of its candidate arimoclomol. This was despite the firm spending billions of kroner on the candidate.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading